Patents Issued in September 29, 2016
  • Publication number: 20160279123
    Abstract: The present invention resides in the discovery that Smad3, a key downstream mediator of TGF-? signaling, plays a critical role in development and progression of cancer. Thus, this application provides for a novel method of treating cancer by inhibiting Smad3 signaling, such as through administration of SIS3, an inhibitor of Smad3. Further provided are compositions and kits useful for treating cancer by way of inhibiting Smad3 signaling.
    Type: Application
    Filed: March 8, 2016
    Publication date: September 29, 2016
    Inventor: HUI YAO LAN
  • Publication number: 20160279124
    Abstract: The present invention provides a method of treating a patient suffering from addiction, having the steps of administering to the patient a controlled release composition comprising an opioid antagonist; and coaching the patient.
    Type: Application
    Filed: March 28, 2016
    Publication date: September 29, 2016
    Inventors: Dan Markel, Brian Newton
  • Publication number: 20160279125
    Abstract: The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide. Novel solid forms of this compound, their utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing them are also object of the present invention.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Natale Alvaro Barbugian, Romualdo Forino, Tiziano Fumagalli, Paolo Orsini
  • Publication number: 20160279126
    Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more analgesic agents and a PDE5 inhibitor. Also disclosed are methods of making and using of the pharmaceutical compositions.
    Type: Application
    Filed: June 2, 2016
    Publication date: September 29, 2016
    Inventor: David A. DILL
  • Publication number: 20160279127
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 29, 2016
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Publication number: 20160279128
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 20, 2016
    Publication date: September 29, 2016
    Inventors: John H. van Duzer, Ralph Mazitschek, Simon Stewart Jones, Min Yang, David Lee Tamang
  • Publication number: 20160279129
    Abstract: This invention relates to solid oral pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methyl sulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate (COMPOUND A) and the use of these formulations for treating proliferative diseases, such as solid tumor diseases.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Daya Verma, Yogita Krishnamachari, Xiaohong Shen, Hanchen Lee, Ping Li, Rajinder Singh, LayChoo Tan
  • Publication number: 20160279130
    Abstract: Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite.
    Type: Application
    Filed: November 13, 2013
    Publication date: September 29, 2016
    Inventors: Michael ZEMEL, Antje BRUCKBAUER, Brooke BAGGETT
  • Publication number: 20160279131
    Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 29, 2016
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Felix THEEUWES, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK
  • Publication number: 20160279132
    Abstract: Compound of Formula I: are described, along with pharmaceutically acceptable salts thereof, compositions containing the same, and methods of use thereof in the treatment of cancer.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 29, 2016
    Inventors: Xiaodong Wang, Jing Liu, Chao Yang, Weihe Zhang, Stephen Frye, Dmitri Kireev
  • Publication number: 20160279133
    Abstract: The present invention refers to a pharmaceutical composition of sildenafil citrate in the form of a suspension for administration orally that comprises water as a vehicle and xanthan gum and hypromellose as suspension agents, that is highly stable and allows the efficient masking of the active ingredient's bitter taste. It also refers to a procedure for the preparation of said suspension and to a container that contains it and that is provided with a dosing device for its administration. This composition of sildenafil citrate in the form of a suspension is suitable for administration orally for the treatment of masculine sexual dysfunction.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Fernando Martínez-Alzamora, Antonia Gómez Calvo, Miguel Rizo Martínez, Nuria Sanz Menéndez
  • Publication number: 20160279134
    Abstract: The invention relates to a pharmaceutical film formulation comprising one or more bitter-tasting drug(s) or pharmaceutically acceptable salts thereof, one or more film formers, a bitterness masker containing one or more inorganic and/or organic salt(s) and at least two monocyclic monoterpenes, and one or more sweetening agents.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: Thomas KOHR, Petra OBERMEIER
  • Publication number: 20160279135
    Abstract: Provided herein are methods, compositions, and kits for treating myeloproliferative disorders or neoplasms, including polycythemia vera, primary myelofibrosis, thrombocythemia, and essential thrombocythemia.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Inventors: Brian Lannutti, Sarah Meadows, Christophe Queva, Matthew Robert Warr, James Andrew Whitney
  • Publication number: 20160279136
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. VIEIRA, Austin B. HUANG, Padmanabh P. BHATT
  • Publication number: 20160279137
    Abstract: The present invention relates to methods for treating an ophthalmic, otic, or nasal infection comprising treating the infected tissue with a suspension composition comprising finafloxacin or a finafloxacin derivative. The present invention also relates to antimicrobial compositions comprising finafloxacin free base or a finafloxacin derivative. The compositions are suitable for the treatment of ophthalmic, otic, or nasal infections.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Inventors: Brent G. Boudreaux, Mark J. Bridle, Bryan H. Huynh, Malay Ghosh, Masood A. Chowhan, Laman Alani, Bhagwati P. Kabra
  • Publication number: 20160279138
    Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Raptor Pharmaceuticals, Inc.
    Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Rodny, David C. Griffith
  • Publication number: 20160279139
    Abstract: The present invention provides a process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising sterile active ingredient(s) such as sterile carbonic anhydrase inhibitors (CAIs) wherein the process does not involve the use of any special equipment's such as ball mill, milling bottle and/or jet mill The present process is simple, cost effective and efficient.
    Type: Application
    Filed: November 5, 2014
    Publication date: September 29, 2016
    Inventors: Mandar V. Shah, Deepak Bahri, Divya Pandit
  • Publication number: 20160279140
    Abstract: This disclosure provides pharmaceutical compositions comprising ceftolozane, pharmaceutical compositions comprising ceftolozane and tazobactam, methods of preparing those compositions, and related methods and uses of these compositions.
    Type: Application
    Filed: March 31, 2016
    Publication date: September 29, 2016
    Inventors: Joseph Terracciano, Nicole Miller Damour, Chun Jiang, Giovanni Fogliato, Giuseppe Alessandro Donadelli, Dario Resemini
  • Publication number: 20160279141
    Abstract: The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Michael R. McKeown, Margaret A. Shipp, Bjoern Chapuy, Kwok-kin Wong, Zhao Chen
  • Publication number: 20160279142
    Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Applicant: Genentech, Inc.
    Inventors: Lori Friedman, Michelle Nannini, Deepak Sampath, Jeffrey Wallin
  • Publication number: 20160279143
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Application
    Filed: November 12, 2015
    Publication date: September 29, 2016
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Publication number: 20160279144
    Abstract: Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of demyelinating diseases.
    Type: Application
    Filed: June 10, 2016
    Publication date: September 29, 2016
    Inventors: James G. Yarger, Steven H. Nye
  • Publication number: 20160279145
    Abstract: Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Hareesh Nair, Bindu Santhamma, Klaus Nickisch
  • Publication number: 20160279146
    Abstract: The invention related to methods of treatment of an individual suffering from or at risk of suffering from a selective estrogen-receptor modulator (SERM) induced adverse drug reaction. The invention additionally relates to a pharmaceutical dosage form, preferably a tablet, comprising a composition for pulsatile, not-continuous release of a compound or a combination of compounds that stimulate the dopamine and/or the noradrenergic system.
    Type: Application
    Filed: November 11, 2014
    Publication date: September 29, 2016
    Applicant: Limoxifen B.V.
    Inventors: Jan Johan Adriaan TUITEN, Konrad Bernardus Everardus BOCKER, Hans Peter Frederik KOPPESCHAAR
  • Publication number: 20160279147
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Applicant: FERRING B.V.
    Inventors: Salah U. AHMED, Jiaxiang TSAO, Anu MAHASHABDE, Diane D. HARRISON
  • Publication number: 20160279148
    Abstract: This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.
    Type: Application
    Filed: April 11, 2016
    Publication date: September 29, 2016
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Publication number: 20160279149
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Application
    Filed: April 11, 2016
    Publication date: September 29, 2016
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Publication number: 20160279150
    Abstract: Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 29, 2016
    Inventors: Klaus SCHIENE, Guenter HAASE, Babette-Yvonne KOEGEL, Elmar FRIDERICHS, Ulrich JAHNEL
  • Publication number: 20160279151
    Abstract: Injectable and oral formulations of a tetracycline compound are described. In one embodiment, the invention pertains to an oral formulation of a 9-aminomethyl tetracycline compound, or a salt thereof, in tablet form or capsule. The formulations may be used, for example, to treat infections.
    Type: Application
    Filed: March 7, 2016
    Publication date: September 29, 2016
    Inventor: Sean M. Johnston
  • Publication number: 20160279152
    Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises minocycline, a magnesium salt, and a sulfite compound in a non-aqueous solvent. In yet another aspect, the topical composition comprises a tetracycline-class drug, a source of magnesium, a monohydric aliphatic alcohol, and a polyol, wherein (i) the ratio between the monohydric aliphatic alcohol and the propylene glycol is in the range of 1:1 to 99:1 by weight and (ii) the tetracycline-class drug is dissolved in the topical composition.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 29, 2016
    Inventors: Xin Chen, Maiko C. Hermsmeier, Diana Lac, Douglas W. Thomas, Noymi Yam, Akira Yamamoto
  • Publication number: 20160279153
    Abstract: The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.
    Type: Application
    Filed: February 1, 2016
    Publication date: September 29, 2016
    Applicant: Salix Pharmaceuticals, Inc.
    Inventors: Joseph Lockhart, Brock Swanson, Lorin K. Johnson
  • Publication number: 20160279154
    Abstract: The invention provides timoquinone-based mitochondrially-targeted antioxidants (MTAs) and methods for their use.
    Type: Application
    Filed: March 3, 2016
    Publication date: September 29, 2016
    Inventors: VLADIMIR P SKULACHEV, MAXIM V SKULACHEV
  • Publication number: 20160279155
    Abstract: Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof. Also provided are kits comprising 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate. Also provided is a method of treating or controlling a disease or condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.
    Type: Application
    Filed: November 6, 2014
    Publication date: September 29, 2016
    Applicant: Aeromics, Inc.
    Inventors: Marc F. PELLETIER, Paul Robert MCGUIRK, George William FARR
  • Publication number: 20160279156
    Abstract: The present invention relates to a composition for preventing or treating colon cancer, containing 3,6-anhydro-L-galactose, and more specifically, provides excellent anti-cancer effects by inducing apoptosis of colon cancer cells and inhibiting the growth of colon cancer cells by using 3,6-anhydro-L-galactose separated from red algae-derived agar and purified.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 29, 2016
    Applicant: Korea University Research and Business Foundation
    Inventors: Nam Joo Kang, Kyoung Heon Kim, In-Geol Choi, Young Ah Kim, Eun-Ju Yun, Sae Young Lee
  • Publication number: 20160279157
    Abstract: The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 29, 2016
    Inventors: Jerome Schentag, Joseph M. Fayad
  • Publication number: 20160279158
    Abstract: The invention relates to glucosamine-enriched plant compositions and their use as a biocide, for instance, in the treatment of skin diseases and/or mucosal diseases. The invention also concerns the use of glucosamine-enriched plant compositions for preventing and/or reducing body odors.
    Type: Application
    Filed: November 4, 2014
    Publication date: September 29, 2016
    Inventors: Yann Mahe, Pierre Edmond Broun, Jwanro Husson, Didier Courtois
  • Publication number: 20160279159
    Abstract: The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.
    Type: Application
    Filed: March 28, 2016
    Publication date: September 29, 2016
    Inventors: Michio Hirano, Caterina Garone
  • Publication number: 20160279160
    Abstract: The present invention relates to compositions comprising spicamycin derivatives, methods of making such compositions, and their use in the treatment and/or prevention of pain, including neuropathic pain.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Applicant: DARA Biosciences, Inc.
    Inventors: Michael Radomsky, Mary Katherine Delmedico, Linda Jett
  • Publication number: 20160279161
    Abstract: The present invention relates to a method of treating or preventing DNA damage in a cell or cellular senescence of a cell or induction of the senescence associated secretory phenotype (SASP) in a cell, or for treating or preventing the effects of aging, or for preventing or treating cellular senescence and/or induction of SASP associated with high caloric intake or obesity, or for reducing the side effects of chemotherapy, radiotherapy, corticoid treatment, anti-retroviral treatment, or PPAR? agonist treatment, comprising administering an effective amount of an NAD+ agonist.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 29, 2016
    Inventors: Lindsay Edward Wu, David Andrew Sinclair
  • Publication number: 20160279162
    Abstract: Disclosed herein are compositions methods related to micelle-based delivery of dermal cosmetic and/or therapeutic materials. Micelles are formed by controlling proportions of hydrophilic and hydrophobic moieties, which then enables surfactants to facilitate formation of micelles and other cylindrical or vesicular nano-scale structures. These nano-scale structures are used to deliver therapeutic materials through the stratum corneum to underlying layers of skin.
    Type: Application
    Filed: November 18, 2014
    Publication date: September 29, 2016
    Inventor: David A. RICHARD
  • Publication number: 20160279163
    Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Inventors: Phillip P. Chan, Wei-Tai Young, Vincent J. Capponi, Thomas D. Golobish, Robert H. Bartlett, Humayra Begum Ali
  • Publication number: 20160279164
    Abstract: Provided is a high-molecular weight conjugate of resorcinol derivatives which is excellent in water solubility and stability and has high antitumor activity even when used in a smaller total drug amount than the resorcinol derivatives. The high-molecular weight conjugate of resorcinol derivatives comprises a structure in which a carboxyl group of polymer moiety having a carboxyl group in the side chain and polyethylene glycol moiety is linked to a hydroxyl group of resorcinol derivatives via an ester bond.
    Type: Application
    Filed: May 20, 2016
    Publication date: September 29, 2016
    Inventors: Masaharu Nakamura, Masayuki Kitagawa, Keiichirou Yamamoto, Chieko Seno
  • Publication number: 20160279165
    Abstract: A method of treating a human subject which is effected by intermittent breathing cycle-coordinated pulse delivery inhalation of gaseous nitric oxide at a concentration of at least 160 ppm, or at a load per cycle of 80 ppm-hour, is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Inventors: Yossef AV-GAY, David GREENBERG, Einav LEVI
  • Publication number: 20160279166
    Abstract: A treating agent for the examination or operation of the large intestine which has high examination precision or facilitates an operation and can be administered with a small amount of water. The treating agent for the examination or operation of the large intestine contains magnesium oxide particles and is used to be orally administered before an examination or operation.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: KYOWA CHEMICAL INDUSTRY CO., LTD.
    Inventors: Yuya YOSHIMURA, Satoru ISHIHAMA
  • Publication number: 20160279167
    Abstract: Disclosed are a method of promoting hair growth or preventing hair loss in a mammal. In one aspect, the method includes administering interdermally or subcutaneously an agent containing an active ingredient comprising bFGF and a pharmaceutically acceptable substance, wherein bFGF is administered in a dose of 1 ?g to 100 ?g per 1 cm2 of the target area of hair growth treatment or hair loss prevention and a composition for use in the method.
    Type: Application
    Filed: July 17, 2015
    Publication date: September 29, 2016
    Inventor: Jaehyun LIM
  • Publication number: 20160279168
    Abstract: The present invention is related to a pharmaceutical composition comprising cells committed to the generation of heart tissue and at least one pharmaceutically acceptable excipient produced according to internationally recognized standards for pharmaceutical product manufacture, a process for the manufacture of such a pharmaceutical composition and a kit for the administration of said pharmaceutical composition which comprises a container containing said pharmaceutical composition.
    Type: Application
    Filed: March 4, 2016
    Publication date: September 29, 2016
    Applicant: Celyad S.A.
    Inventors: Vinciane GAUSSIN, Roland Gordon-Beresford, Christian Homsy
  • Publication number: 20160279169
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Application
    Filed: June 13, 2016
    Publication date: September 29, 2016
    Applicants: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co. Ltd.
    Inventors: Daniel OFFEN, Michal DADON-NACHUM, Tali BEN-ZUR, Eldad MELAMED, David YAFFE
  • Publication number: 20160279170
    Abstract: A method to provide an inflated decellularized extracellular matrix of a mammalian organ or a vascularized portion thereof, or a mammalian vascularized tissue or a vascularized portion thereof, an inflated decellularized extracellular matrix of a mammalian organ or a vascularized portion thereof, or a mammalian vascularized tissue or a vascularized portion thereof, and uses thereof, are provided.
    Type: Application
    Filed: March 24, 2016
    Publication date: September 29, 2016
    Inventors: Aleksandr Katane, Dominique Seetapun, Jeffrey Ross
  • Publication number: 20160279171
    Abstract: Provided herein are compositions comprising mononuclear cells from human placental perfusate and methods of using such cells, including using the cells together with hematopoietic cells, for example to establish chimerism, reduce the severity or duration of graft versus host disease, treat or ameliorate symptoms of sarcopenia, metabolic disorders and hematologic disorders, such as hematologic malignancies, and treat or ameliorate symptoms of ischemic encephalopathy (e.g., hypoxic ischemic encephalopathy) and other central nervous system injuries.
    Type: Application
    Filed: November 14, 2014
    Publication date: September 29, 2016
    Applicant: Anthrogenesis Corporation
    Inventors: Jodi P. Gurney, Xiaokui Zhang, Stacy Herb, Robert J. Hariri
  • Publication number: 20160279172
    Abstract: Lobster hemolymph and compositions derived therefrom for the prevention or treatment of viral diseases or cancer by systemic administration.
    Type: Application
    Filed: June 8, 2016
    Publication date: September 29, 2016
    Inventor: Robert C. Bayer